PROMIS研究II:特发性炎性肌病死因随时间的变迁
年龄性别调整标准化死亡比为6.2(95%CI 5.7-6.7),1、3、10年累积生存率分别为92.6%、88.6%、80.5%。主要死因为间质性肺病、恶性肿瘤、心血管疾病和感染(各约18.8%),且死因构成随时间从间质性肺病/感染向恶性肿瘤/心血管疾病转变。
要点
- 特发性炎性肌病患者死亡率显著高于一般人群,标准化死亡比6.2。
- 前三位主要死因为间质性肺病、恶性肿瘤、心血管疾病,感染紧随其后。
- 男性、淋巴细胞减少、高铁蛋白及抗MDA5、抗TIF1γ、抗Ro52抗体提示死亡风险增高。
核心结论
- 特发性炎性肌病患者死亡率显著高于一般人群,死因构成随病程推移发生转变。
- 基于肌炎特异性抗体的分类有助于深入理解疾病发病机制与管理。
研究设计与样本
- 多中心前瞻性队列研究,纳入4534例中国特发性炎性肌病患者。
- 计算年龄性别调整标准化死亡比,分析死因,并用多变量Cox比例风险模型识别全因死亡危险因素。
主要发现
- 1年、3年、10年累积生存率分别为92.6%、88.6%、80.5%。
- 主要死因包括间质性肺病(18.8%)、恶性肿瘤(18.8%)、心血管疾病(18.8%)和感染(18.6%),死因随时间从间质性肺病/感染向恶性肿瘤/心血管疾病转变。
- 死亡危险因素包括男性、淋巴细胞减少、高血清铁蛋白、抗MDA5抗体、抗TIF1γ抗体和抗Ro52抗体。
临床怎么用
- 临床应关注特发性炎性肌病患者的高死亡风险,尤其合并上述危险因素者。
- 随访中需根据病程阶段警惕死因构成变化,早期关注间质性肺病与感染,后期关注恶性肿瘤与心血管疾病。
局限性
- 抗合成酶综合征和免疫介导坏死性肌病可能存在低估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Idiopathic inflammatory myopathies (IIMs) are heterogeneous autoimmune diseases with variable long-term outcomes. OBJECTIVE: To determine the prognosis of IIM. METHODS: This multicenter, prospective cohort study included Chinese patients with IIM. We calculated the standardized mortality ratios adjusted for age and sex, analyzed causes of death, and identified risk factors for all-cause mortality using a multivariable Cox proportional hazards model. RESULTS: A total of 4534 patients were included, with 2902 dermatomyositis, 592 polymyositis, 927 anti-synthetase syndrome, and 113 immune-mediated necrotizing myopathy. Five hundred ten patients died with a median follow-up time of 46 months. The overall standardized mortality ratio was 6.2 (95% CI: 5.7-6.7). Cumulative survival rates at 1, 3, and 10 years were 92.6%, 88.6%, and 80.5%, respectively. Leading causes of death included interstitial lung diseases (18.8%), malignancies (18.8%), cardiovascular diseases (18.8%), and infections (18.6%), which shifted over time (from interstitial lung disease/infection to malignancies/cardiovascular diseases). Risk factors for mortality included male, lymphopenia, high serum ferritin, anti-melanoma differentiation-associated gene 5, anti-transcription intermediary factor 1 gamma (anti-TIF1γ), and anti-Ro 52 antibodies. LIMITATIONS: Underestimation of anti-synthetase syndrome and immune-mediated necrotizing myositis. CONCLUSION: IIM patients had significantly higher mortality than the general population, with variable causes of death and distinct risks based on myositis-specific antibodies. Myositis-associated autoantibodies-based classification may provide deeper insights into pathogenesis and management of IIM.
引用
- Yu C, Wu C, Jin S, et al. The Prospective Registry Of MyositIS (PROMIS): II. Temporal shifts in causes of death among patients with idiopathic inflammatory myopathies. J Am Acad Dermatol. 2025. PMID: 40653049. doi:10.1016/j.jaad.2025.06.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。